| Age Group, y . | Symptom Statusb . | Total No. . | Rhinovirus-Positive Encounters, No. (%) . |
|---|---|---|---|
| All encounters | |||
| <5 | All | 651 | 170 (26.1) |
| Asymptomatic | 546 | 138 (25.3) | |
| Symptomatic | 105 | 32 (30.5) | |
| 5–11 | All | 885 | 143 (16.2) |
| Asymptomatic | 824 | 127 (15.4) | |
| Symptomatic | 61 | 16 (26.2) | |
| 12–17 | All | 506 | 47 (9.3) |
| Asymptomatic | 475 | 43 (9.1) | |
| Symptomatic | 31 | 4 (12.9) | |
| 18–49 | All | 7716 | 475 (6.2) |
| Asymptomatic | 6303 | 339 (5.4) | |
| Symptomatic | 1413 | 136 (9.6) | |
| 50–64 | All | 3795 | 196 (5.2) |
| Asymptomatic | 2795 | 102 (3.7) | |
| Symptomatic | 1000 | 94 (9.4) | |
| ≥65 | All | 908 | 35 (3.9) |
| Asymptomatic | 766 | 27 (3.5) | |
| Symptomatic | 142 | 8 (5.6) | |
| All age groups | All | 14 464 | 1066 (7.4) |
| Asymptomatic | 11 709 | 776 (6.6) | |
| Symptomatic | 2755 | 290 (10.5) | |
| Virus-positive encounters | |||
| <5 | All | 221 | 170 (76.9) |
| Asymptomatic | 158 | 138 (87.3) | |
| Symptomatic | 63 | 32 (50.8) | |
| 5–11 | All | 188 | 143 (76.1) |
| Asymptomatic | 157 | 127 (80.9) | |
| Symptomatic | 31 | 16 (51.6) | |
| 12–17 | All | 64 | 47 (73.4) |
| Asymptomatic | 57 | 43 (75.4) | |
| Symptomatic | 7 | 4 (57.1) | |
| 18–49 | All | 708 | 475 (67.1) |
| Asymptomatic | 441 | 339 (76.9) | |
| Symptomatic | 267 | 136 (50.9) | |
| 50–64 | All | 322 | 196 (60.9) |
| Asymptomatic | 156 | 102 (65.4) | |
| Symptomatic | 166 | 94 (56.6) | |
| ≥65 | All | 64 | 35 (54.7) |
| Asymptomatic | 40 | 27 (67.5) | |
| Symptomatic | 24 | 8 (33.3) | |
| All age groups | All | 1569 | 1066 (67.9) |
| Asymptomatic | 1009 | 776 (76.9) | |
| Symptomatic | 560 | 290 (51.8) | |
| Age Group, y . | Symptom Statusb . | Total No. . | Rhinovirus-Positive Encounters, No. (%) . |
|---|---|---|---|
| All encounters | |||
| <5 | All | 651 | 170 (26.1) |
| Asymptomatic | 546 | 138 (25.3) | |
| Symptomatic | 105 | 32 (30.5) | |
| 5–11 | All | 885 | 143 (16.2) |
| Asymptomatic | 824 | 127 (15.4) | |
| Symptomatic | 61 | 16 (26.2) | |
| 12–17 | All | 506 | 47 (9.3) |
| Asymptomatic | 475 | 43 (9.1) | |
| Symptomatic | 31 | 4 (12.9) | |
| 18–49 | All | 7716 | 475 (6.2) |
| Asymptomatic | 6303 | 339 (5.4) | |
| Symptomatic | 1413 | 136 (9.6) | |
| 50–64 | All | 3795 | 196 (5.2) |
| Asymptomatic | 2795 | 102 (3.7) | |
| Symptomatic | 1000 | 94 (9.4) | |
| ≥65 | All | 908 | 35 (3.9) |
| Asymptomatic | 766 | 27 (3.5) | |
| Symptomatic | 142 | 8 (5.6) | |
| All age groups | All | 14 464 | 1066 (7.4) |
| Asymptomatic | 11 709 | 776 (6.6) | |
| Symptomatic | 2755 | 290 (10.5) | |
| Virus-positive encounters | |||
| <5 | All | 221 | 170 (76.9) |
| Asymptomatic | 158 | 138 (87.3) | |
| Symptomatic | 63 | 32 (50.8) | |
| 5–11 | All | 188 | 143 (76.1) |
| Asymptomatic | 157 | 127 (80.9) | |
| Symptomatic | 31 | 16 (51.6) | |
| 12–17 | All | 64 | 47 (73.4) |
| Asymptomatic | 57 | 43 (75.4) | |
| Symptomatic | 7 | 4 (57.1) | |
| 18–49 | All | 708 | 475 (67.1) |
| Asymptomatic | 441 | 339 (76.9) | |
| Symptomatic | 267 | 136 (50.9) | |
| 50–64 | All | 322 | 196 (60.9) |
| Asymptomatic | 156 | 102 (65.4) | |
| Symptomatic | 166 | 94 (56.6) | |
| ≥65 | All | 64 | 35 (54.7) |
| Asymptomatic | 40 | 27 (67.5) | |
| Symptomatic | 24 | 8 (33.3) | |
| All age groups | All | 1569 | 1066 (67.9) |
| Asymptomatic | 1009 | 776 (76.9) | |
| Symptomatic | 560 | 290 (51.8) | |
Excludes n = 3 samples where age of participant is unknown; none of these samples were positive for rhinovirus; these are row percentages.
A symptomatic encounter was defined as a study encounter in which the participant reported any new or worsening symptom on the enrollment questionnaire and is not limited to symptoms required for enrollment; an asymptomatic encounter was defined as a study encounter in which the participant did not report any new or worsening symptoms on the enrollment questionnaire.
| Age Group, y . | Symptom Statusb . | Total No. . | Rhinovirus-Positive Encounters, No. (%) . |
|---|---|---|---|
| All encounters | |||
| <5 | All | 651 | 170 (26.1) |
| Asymptomatic | 546 | 138 (25.3) | |
| Symptomatic | 105 | 32 (30.5) | |
| 5–11 | All | 885 | 143 (16.2) |
| Asymptomatic | 824 | 127 (15.4) | |
| Symptomatic | 61 | 16 (26.2) | |
| 12–17 | All | 506 | 47 (9.3) |
| Asymptomatic | 475 | 43 (9.1) | |
| Symptomatic | 31 | 4 (12.9) | |
| 18–49 | All | 7716 | 475 (6.2) |
| Asymptomatic | 6303 | 339 (5.4) | |
| Symptomatic | 1413 | 136 (9.6) | |
| 50–64 | All | 3795 | 196 (5.2) |
| Asymptomatic | 2795 | 102 (3.7) | |
| Symptomatic | 1000 | 94 (9.4) | |
| ≥65 | All | 908 | 35 (3.9) |
| Asymptomatic | 766 | 27 (3.5) | |
| Symptomatic | 142 | 8 (5.6) | |
| All age groups | All | 14 464 | 1066 (7.4) |
| Asymptomatic | 11 709 | 776 (6.6) | |
| Symptomatic | 2755 | 290 (10.5) | |
| Virus-positive encounters | |||
| <5 | All | 221 | 170 (76.9) |
| Asymptomatic | 158 | 138 (87.3) | |
| Symptomatic | 63 | 32 (50.8) | |
| 5–11 | All | 188 | 143 (76.1) |
| Asymptomatic | 157 | 127 (80.9) | |
| Symptomatic | 31 | 16 (51.6) | |
| 12–17 | All | 64 | 47 (73.4) |
| Asymptomatic | 57 | 43 (75.4) | |
| Symptomatic | 7 | 4 (57.1) | |
| 18–49 | All | 708 | 475 (67.1) |
| Asymptomatic | 441 | 339 (76.9) | |
| Symptomatic | 267 | 136 (50.9) | |
| 50–64 | All | 322 | 196 (60.9) |
| Asymptomatic | 156 | 102 (65.4) | |
| Symptomatic | 166 | 94 (56.6) | |
| ≥65 | All | 64 | 35 (54.7) |
| Asymptomatic | 40 | 27 (67.5) | |
| Symptomatic | 24 | 8 (33.3) | |
| All age groups | All | 1569 | 1066 (67.9) |
| Asymptomatic | 1009 | 776 (76.9) | |
| Symptomatic | 560 | 290 (51.8) | |
| Age Group, y . | Symptom Statusb . | Total No. . | Rhinovirus-Positive Encounters, No. (%) . |
|---|---|---|---|
| All encounters | |||
| <5 | All | 651 | 170 (26.1) |
| Asymptomatic | 546 | 138 (25.3) | |
| Symptomatic | 105 | 32 (30.5) | |
| 5–11 | All | 885 | 143 (16.2) |
| Asymptomatic | 824 | 127 (15.4) | |
| Symptomatic | 61 | 16 (26.2) | |
| 12–17 | All | 506 | 47 (9.3) |
| Asymptomatic | 475 | 43 (9.1) | |
| Symptomatic | 31 | 4 (12.9) | |
| 18–49 | All | 7716 | 475 (6.2) |
| Asymptomatic | 6303 | 339 (5.4) | |
| Symptomatic | 1413 | 136 (9.6) | |
| 50–64 | All | 3795 | 196 (5.2) |
| Asymptomatic | 2795 | 102 (3.7) | |
| Symptomatic | 1000 | 94 (9.4) | |
| ≥65 | All | 908 | 35 (3.9) |
| Asymptomatic | 766 | 27 (3.5) | |
| Symptomatic | 142 | 8 (5.6) | |
| All age groups | All | 14 464 | 1066 (7.4) |
| Asymptomatic | 11 709 | 776 (6.6) | |
| Symptomatic | 2755 | 290 (10.5) | |
| Virus-positive encounters | |||
| <5 | All | 221 | 170 (76.9) |
| Asymptomatic | 158 | 138 (87.3) | |
| Symptomatic | 63 | 32 (50.8) | |
| 5–11 | All | 188 | 143 (76.1) |
| Asymptomatic | 157 | 127 (80.9) | |
| Symptomatic | 31 | 16 (51.6) | |
| 12–17 | All | 64 | 47 (73.4) |
| Asymptomatic | 57 | 43 (75.4) | |
| Symptomatic | 7 | 4 (57.1) | |
| 18–49 | All | 708 | 475 (67.1) |
| Asymptomatic | 441 | 339 (76.9) | |
| Symptomatic | 267 | 136 (50.9) | |
| 50–64 | All | 322 | 196 (60.9) |
| Asymptomatic | 156 | 102 (65.4) | |
| Symptomatic | 166 | 94 (56.6) | |
| ≥65 | All | 64 | 35 (54.7) |
| Asymptomatic | 40 | 27 (67.5) | |
| Symptomatic | 24 | 8 (33.3) | |
| All age groups | All | 1569 | 1066 (67.9) |
| Asymptomatic | 1009 | 776 (76.9) | |
| Symptomatic | 560 | 290 (51.8) | |
Excludes n = 3 samples where age of participant is unknown; none of these samples were positive for rhinovirus; these are row percentages.
A symptomatic encounter was defined as a study encounter in which the participant reported any new or worsening symptom on the enrollment questionnaire and is not limited to symptoms required for enrollment; an asymptomatic encounter was defined as a study encounter in which the participant did not report any new or worsening symptoms on the enrollment questionnaire.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
